{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T10:34:54Z","timestamp":1648982094684},"reference-count":0,"publisher":"Pakistan Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pak Med Assoc"],"abstract":"<jats:p>Objectives: 1:To determine outcome of first relapse of Hodgkin Lymphoma with standard dose chemotherapy. 2: To identify the prognostic factors predicting survival outcome in pediatric relapsed Hodgkin lymphoma. Methods: This was a retrospective analysis of 43 patients with HL who relapsed at least 3 months after completion of initial treatment from January 2001 to December 2010. Probabilities of OS, EFS and cumulative incidence were calculated by Kaplan-Meier method. Log rank tests were used to compare survival curves and p-value&lt;0.05 was considered significant Results: Median age at relapse was 11\u00b1 3.3 years. In 72% of patients EPIC chemotherapy was employed. Median follow up of this cohort was 62 months (range 4-187 months). OS and EFS at 10 years was 54% and 35% respectively. On univariate analysis; initial disease stage (p=0.021), stage at relapse (p=0.003), treatment protocol (p=0.005), treatment responsiveness at initial two cycles of salvage chemotherapy (p=0.002) and at the end of treatment assessment (p=0.0009) were statistically significant factors. Multivariate cox regression analysis revealed disease stage at relapse (p=0.004), chemotherapy regimen (p=0.025) and end of treatment disease evaluation (p=0.005) as the statistically significant variables. Conclusion: First relapse of HL is potentially salvageable with standard dose chemotherapy with\/without radiation. The patients with early stage at relapse and those with chemo-responsiveness can be effectively treated without ASCT. We observed improved outcome with EPIC chemotherapy regimen for the patients who had DFI of more 2 years.<\/jats:p>","DOI":"10.47391\/jpma.1114","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T16:52:48Z","timestamp":1605891168000},"page":"1-15","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of first relapse of Hodgkin lymphoma: Single Institution experience"],"prefix":"10.47391","author":[{"family":"Najma Shaheen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ata Ur Rehman Maaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Muhammad Saghir Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Admin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26547","published-online":{"date-parts":[[2020,11,20]]},"container-title":["Journal of the Pakistan Medical Association"],"original-title":[],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T15:11:08Z","timestamp":1614697868000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojs.jpma.org.pk\/index.php\/public_html\/article\/view\/664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":0,"URL":"https:\/\/doi.org\/10.47391\/jpma.1114","relation":{},"ISSN":["0030-9982"],"issn-type":[{"value":"0030-9982","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,20]]}}}